TLDR Tripterygium wilfordii multiglycoside effectively reduced prostate enlargement in rats without harmful effects.
The study evaluated the effects of Tripterygium wilfordii multiglycoside (GTW) on testosterone-induced benign prostatic hyperplasia (BPH) in 45 rats divided into five groups. GTW was administered at doses of 10 and 20 mg/kg for 14 days. Results showed that GTW significantly reduced prostate weight, prostatic index, testosterone and dihydrotestosterone (DHT) levels in both serum and prostate, and serum prostate-specific antigen (PSA) levels compared to the BPH group. Histopathological examination confirmed that GTW inhibited prostatic hyperplasia without affecting liver and renal functions, suggesting GTW as a potential therapy for BPH.
44 citations,
January 2012 in “Food and chemical toxicology” Ursolic acid can shrink the prostate and lower a hormone linked to prostate growth in rats.
72 citations,
January 2011 in “Current Pharmaceutical Design” S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.
June 2023 in “Clinica Chimica Acta” Finasteride and dutasteride effectively reduce DHT in hair, which may help evaluate their treatment success for hair loss.
215 citations,
November 2006 in “Journal of The American Academy of Dermatology” Dutasteride more effective for hair growth, but has more side effects than finasteride.
65 citations,
October 1999 in “Journal of The American Academy of Dermatology” Finasteride effectively reduces hair loss by decreasing androgen levels.
6 citations,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.
59 citations,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride reduces scalp DHT levels, potentially treating male pattern baldness.
